Update on Diagnosis and Management of Migraines

Size: px
Start display at page:

Download "Update on Diagnosis and Management of Migraines"

Transcription

1 Update on Diagnosis and Management of Migraines Joel J. Heidelbaugh, MD, FAAFP, FACG Clinical Professor Departments of Family Medicine and Urology University of Michigan

2 Learning Objectives To distinguish migraine headache from other headaches using Clinical findings Screening tools Evidence-based guidelines To assess the value of new medications and new delivery systems to enhance individualized treatment for patients with acute migraine headache To increase patient engagement within a collaborative care model that emphasizes Education Adherence Communication among the healthcare team members

3 Migraine Is Common Migraine Prevalence, % Age, years Female Male US Prevalence (%) Female Male Sex 17 6 Race White Black Highest prevalence Age y 24 7 Lipton RB, et al. Headache. 2001;41: ; Lipton RB, et al. Neurology. 2007;68:

4 Migraine Is Debilitating Sexual life Love Finding friends Social position Leisure time Finances Family situation Pursuing studies Attendance at work Making career Very negative influence Quite negative influence Some negative influence Percentage of Pts with Migraine (N = 423) Linde M, Dahlöf C. Cephalalgia. 2004;24:

5 What Happens During a Migraine Attack? Clinical Phases of Migraine 1 hour ~4-72 hours Prodrome Fatigue Food craving Muscle pain Cognitive change Mood change Sensory disruption Aura (if present) Visual Scintillating scotoma Sensory Motor Headache Localization Throbbing Nausea Vomiting Photophobia Phonophobia Postdrome Fatigue Gastrointestinal upset Cognitive change Muscle pain Mood change Adapted from American Migraine Foundation. df. Accessed October 19, 2015.

6 Differential Diagnosis of Primary Headache Sinus headaches or infection often misdiagnosed when correct diagnosis is migraine In 90% of cases, clinician- or selfdiagnosed sinus headache is migraine American Headache Society. Accessed October 19, 2015.

7 Diagnosis: Importance of Headache History How does the headache begin? Precipitating event, illness, injury Frequency and patterns Any significant changes Location Quality and intensity Time to peak intensity Duration Warning symptoms and aura Associated symptoms and level of disability Triggers and aggravating or relieving factors Headache diary is helpful

8 Migraine vs Tension Headache: A Common Misdiagnosis Migraine 2 of the following 4 Unilateral (59% of migraines) Pulsating (85% of migraines) Moderate-severe intensity Aggravation by routine physical activity 1 of the following Nausea/vomiting (73% of migraines) Photophobia/phonophobia (~80% of migraines) Not attributable to another disorder Tension-type 2 of the following Bilateral Not pulsating Mild-moderate intensity Not aggravated by routine physical activity No nausea/vomiting One or neither: photophobia/phonophobia Not attributable to another disorder Headache Classification Committee of the International Headache Society. Cephalalgia. 2013;33: ; Lipton RB, et al. Headache. 2001;41:

9 Common Migraine Triggers Irregular meals, dehydration Irregular caffeine, chocolate, nuts, bananas, etc Irregular sleep (particularly excessive sleep) Weather, changes in weather Light, sunlight exposure Sensitivity to odors (osmophobia) Stress or let-down from stress Air travel, change in barometric pressure Menstrual period Hoffmann J, et al. Curr Pain Headache Rep. 2013;17:

10 Medications That Exacerbate Migraines Oral contraceptives Hormone replacement Selective serotonin reuptake inhibitors Steroids (tapering) Decongestants Short-acting sedatives Some bone density medications MacGregor EA. Curr Pain Headache Rep. 2009;13: ; Nierenburg Hdel C, et al. Headache. 2015;55: ; Allais G, et al. Neurol Sci. 2009;30(suppl 1):S15-S17.

11 Red Flags: SSNOOP S Systemic involvement (fever, myalgias, weight loss) Systemic disease (cancer, AIDS) N Neurologic symptoms or signs O Onset sudden (thunderclap headache) O Onset after age 40 years P Pattern of change: progressive headache/fewer headache-free periods; change in type of headache Be alert to signs/symptoms of secondary headache Dodick DW. Adv Stud Med. 2003;3:87-92.

12 Treatment of Acute Migraine: Triptans Selective 5-HT 1B/1D receptor agonists Pretreatment pain severity strongest predictor of pain relief Patients who do not respond to one triptan may respond to another Triptan Route Dose (mg) Sumatriptan Oral, a subcutaneous, nasal, iontophoretic patch Rizatriptan Oral, ODT 5, 10 Oral: 25, 50, 100; nasal: 5, 20; injection: 4, 6; patch: 6.5 Zolmitriptan Oral, ODT, nasal Oral, ODT: 2.5, 5; nasal: 5 Almotriptan Oral 6.25, 12.5 Eletriptan Oral 20, 40 Naratriptan Oral 1, 2.5 Frovatriptan Oral 2.5 a Combination with naproxen also approved in adult and pediatric patients. 5-HT = 5-hydroxytriptan; ODT = orally disintegrating tablet. Dahlöf CG. Cephalalgia. 2006;26:

13 Treatment of Acute Migraine: Ergots, Diclofenac Ergots Also 5-HT 1B/1D receptor agonists More side effects than triptans but longer lasting Less frequently used Formulations DHE mesylate (tablet, injection, nasal spray; orally inhaled formulation in development) Ergotamine tartrate Ergotamine tartrate + caffeine Diclofenac potassium for oral solution (packets) NSAID

14 Nonspecific Treatments Antiemetics Combination NSAIDs Opiates (only for limited use in very severe migraine) Corticosteroid (intravenous) (rescue therapy) Butalbital/aspirin/caffeine: approved for tension headache; sometimes used for migraine, but not appropriate for this purpose

15 Acute Treatment Principles Treat at least 2 attacks with the same medication If medication is ineffective: Ensure that no other medications are interfering with response Treat early in the attack Maximize dose Change formulation/route of administration Change drug Add drug? combination therapy (eg, sumatriptan/naproxen)? prophylactic treatments

16 American Migraine Prevalence and Prevention Criteria for Use of Preventive Treatment for Episodic Migraine Epidemiologic studies suggest that approximately 38% of migraineurs benefit from preventive therapies, but only 11% currently receive them Headache- Related Impairment Headache Frequency, Days per Month None Consider Offer Offer Some Consider Offer Offer Offer Severe/bedrest Consider Offer Offer Offer Offer Lipton RB, Silberstein SD. Headache. 2015;55(suppl 2): ; Silberstein SD, et al. Neurology. 2012;78: ; Lipton RB, et al. Neurology. 2007;68:

17 Lifestyle Modification: Consistency Is Key Don t skip meals Sleep Caffeine <200 mg/d Six 8-oz glasses of water per day Prophylactic medications Exercise

18 Behavioral Interventions and Collaborative Care NPs, PAs, Physicians Psychology/ Behavioral Specialists Physical Therapy/ Occu pational Therapy Techniques for All Patients Education x x x X Medical communication x x x x Adherence x x x x Relaxation x x x Stress x x Cognitive behavioral therapy x Techniques Based on Patient Presentation Biofeedback x x x Dialectic behavioral therapy Buse DC. Accessed October 19, x x x

19 Prevention of Episodic Migraine: FDA-Approved Agents Start with the lowest dose and increase weekly to desired effect Sodium valproate, divalproex sodium Formulation Tablets, immediate-/ delayed-release capsules Starting Maintenance Dose (mg/d) Propranolol Tablets, oral solution Timolol Tablets Topiramate Tablets, sprinkle capsules FDA = Food and Drug Administration. Reddy DH. Exp Rev Clin Pharmacol. 2013; 6:

20 Treatments Also Used for Prophylaxis NSAIDs Other β-blockers Tricyclic antidepressants (eg, amitriptyline) Gabapentin Angiotensin-converting enzyme inhibitors, calcium channel blockers Petasites (butterbur root) Magnesium Vitamin B2 (riboflavin) Coenzyme Q10 D Amico D, et al. Neuropsychiatr Dis Treat. 2008;4:

21 Principles of Preventive Pharmacotherapy Start at a low dose Give each treatment an adequate trial Preventive pharmacotherapy should be continued for at least several months Avoid interfering, overused, and contraindicated drugs Re-evaluate therapy Women of childbearing potential should understand risks Involve patients in their care to maximize adherence Consider comorbidities and choose medications to treat several coexisting disorders where possible Choose a drug based on efficacy, patient preferences, headache profile, adverse effects D Amico D, et al. Neuropsychiatr Dis Treat. 2008;4:

22 On the Horizon: Potential New Medications/Formulations for Migraine Sumatriptan in fast-acting, dry-powder intranasal form Orally inhaled DHE CGRP-blocking monoclonal antibodies Small-molecule CGRP receptor antagonists Neurally acting antimigraine agents that target 5-HT 1F receptors COL-144 Glutamate receptor antagonists

23 Summary Emphasize to patients the importance of keeping a headache diary to identify triggers and nature of headache and to assess treatment progress Differentiate between migraine and other primary headaches to ensure early and appropriate treatment Treat at least 2 migraines with same medication; consider alternatives if medication remains ineffective When starting preventive pharmacotherapy, start at low dose, consider comorbidities, and respect patient concerns and preferences Participate in a collaborative care model of migraine to improve communication, involve patients in decision making, and focus on prevention

24 Q & A

How do we treat migraine? New SIGN Guidelines

How do we treat migraine? New SIGN Guidelines How do we treat migraine? New SIGN Guidelines Managing your migraine Migraine Trust, Edinburgh 2018 Callum Duncan Consultant Neurologist Aberdeen Royal Infirmary Chair SIGN Guideline 155 Premonitory Mood

More information

ADVANCES IN MIGRAINE MANAGEMENT

ADVANCES IN MIGRAINE MANAGEMENT ADVANCES IN MIGRAINE MANAGEMENT Joanna Girard Katzman, M.D.MSPH Assistant Professor, Dept. of Neurology Project ECHO, Chronic Pain Program University of New Mexico Outline Migraine throughout the decades

More information

MIGRAINE UPDATE. Objectives & Disclosures. Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment.

MIGRAINE UPDATE. Objectives & Disclosures. Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment. MIGRAINE UPDATE Karen L. Bremer, MD November 16, 2018 Objectives & Disclosures Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment. Disclosure: I am

More information

10/17/2017 CHRONIC MIGRAINES BOTOX: TO INJECT OR NOT INJECT? IN CHRONIC MIGRAINE PROPHYLAXIS OBJECTIVES PATIENT CASE EPIDEMIOLOGY EPIDEMIOLOGY

10/17/2017 CHRONIC MIGRAINES BOTOX: TO INJECT OR NOT INJECT? IN CHRONIC MIGRAINE PROPHYLAXIS OBJECTIVES PATIENT CASE EPIDEMIOLOGY EPIDEMIOLOGY BOTOX: TO INJECT OR NOT INJECT? IN CHRONIC MIGRAINE PROPHYLAXIS OBJECTIVES JENNIFER SHIN, PHARMD PGY2 AMBULATORY CARE PHARMACY RESIDENT COMMUNITYCARE HEALTH CENTERS PHARMACOTHERAPY ROUNDS OCTOBER 20, 2017

More information

HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in

HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in Anesthesia and Neurology Harvard Medical School Limited time

More information

Strategies in Migraine Care

Strategies in Migraine Care Strategies in Migraine Care Julie L. Roth, MD Rhode Island Hospital Assistant Professor, Neurology The Warren Alpert Medical School of Brown University March 28, 2015 Financial Disclosures None. Objectives

More information

Faculty Disclosures. Learning Objectives. Acute Treatment Strategies

Faculty Disclosures. Learning Objectives. Acute Treatment Strategies WWW.AMERICANHEADACHESOCIETY.ORG Acute Treatment Strategies Content developed by: Lawrence C. Newman, MD, FAHS Donna Gutterman, PharmD Faculty Disclosures LAWRENCE C. NEWMAN, MD, FAHS Dr. Newman has received

More information

Migraine much more than just a headache

Migraine much more than just a headache Migraine much more than just a headache Session hosted by Teva UK Limited PUU4 11:15 12:15 UK/NHSS/18/0021b Date of Preparation: August 2018 The views expressed in this presentation are those of the speaker

More information

Goals. Primary Headache Syndromes. One-Year Prevalence of Common Headache Disorders

Goals. Primary Headache Syndromes. One-Year Prevalence of Common Headache Disorders Goals One-Year Prevalence of Common Headache Disorders Impact of primary headache syndromes Non pharmacologic Rx of migraine individualized to patient triggers Complementary and alternative Rx of migraine

More information

MEASURE #3: PREVENTIVE MIGRAINE MEDICATION PRESCRIBED Headache

MEASURE #3: PREVENTIVE MIGRAINE MEDICATION PRESCRIBED Headache MEASURE #3: PREVENTIVE MIGRAINE MEDICATION PRESCRIBED Headache Measure Description Percentage of patients age 18 years old and older diagnosed with migraine headache whose migraine frequency is 4 migraine

More information

Case Presentation. Case Presentation. Case Presentation. Truths about Headaches (2017) Most headaches were muscle-tension headaches

Case Presentation. Case Presentation. Case Presentation. Truths about Headaches (2017) Most headaches were muscle-tension headaches Agenda Case presentation Migraine Morphology Primary and Premonitory Phase Secondary Headache Aura Headache Primer on Pain Medication Overuse Headache Case Presentation RT is a 25 year old woman with daily

More information

Çiçek Wöber-Bingöl HEADACHE UNIT FOR CHILDREN AND ADOLESCENCE

Çiçek Wöber-Bingöl HEADACHE UNIT FOR CHILDREN AND ADOLESCENCE Headache in children and adolescents Çiçek Wöber-Bingöl HEADACHE UNIT FOR CHILDREN AND ADOLESCENCE Dept. of Psychiatry of Childhood and Adolescence Medical University of Vienna, Vienna, Austria Impact

More information

MIGRAINE A MYSTERY HEADACHE

MIGRAINE A MYSTERY HEADACHE MIGRAINE A MYSTERY HEADACHE The migraine is a chronic neurological disease that is characterized by moderate to severe episodes of headache that is mostly associated with other central nervous system (CNS)

More information

Faculty Disclosure. Karen L. Bremer, MD. Dr. Bremer has listed no financial interest/arrangement that would be considered a conflict of interest.

Faculty Disclosure. Karen L. Bremer, MD. Dr. Bremer has listed no financial interest/arrangement that would be considered a conflict of interest. Faculty Disclosure Karen L. Bremer, MD Dr. Bremer has listed no financial interest/arrangement that would be considered a conflict of interest. HEADACHE UPDATE Karen L. Bremer, MD November 10, 2017 karen.bremer@creighton.edu

More information

Migraine Management. Jane Melling Headache nurse Mater Misericordiae Hospital

Migraine Management. Jane Melling Headache nurse Mater Misericordiae Hospital Migraine Management Jane Melling Headache nurse Mater Misericordiae Hospital Migraine facts Among the most common disorders of the nervous system 3 rd most prevalent medical disorder on the planet (lancet

More information

Management of headache

Management of headache Management of headache TJ Steiner Imperial College London Based on European principles of management of common headache disorders TJ Steiner, K Paemeleire, R Jensen, D Valade, L Savi, MJA Lainez, H-C Diener,

More information

OH, MY ACHING HEAD! I HAVE NO DISCLOSURES OR CONFLICTS OF INTERESTS TO DECLARE MANAGING HEADACHE IN THE OUTPATIENT SETTING SECONDARY HEADACHES

OH, MY ACHING HEAD! I HAVE NO DISCLOSURES OR CONFLICTS OF INTERESTS TO DECLARE MANAGING HEADACHE IN THE OUTPATIENT SETTING SECONDARY HEADACHES 1 JUSTIN A. OSSMAN, MD CHATTANOOGA FAMILY MEDICINE UPDATE OH, MY ACHING HEAD! MANAGING HEADACHE IN THE OUTPATIENT SETTING 2 I HAVE NO DISCLOSURES OR CONFLICTS OF INTERESTS TO DECLARE OBJECTIVES International

More information

Adult & Pediatric Patients. Stanford Health Care, Division Pain Medicine

Adult & Pediatric Patients. Stanford Health Care, Division Pain Medicine Acute Treatment Strategies in Adult & Pediatric Patients Theresa Mallick Searle, MS, RN BC, ANP BC Disclosures Speakers Bureau: Allergan, Depomed Acute Treatment Strategies in Adult & Pediatric Patients

More information

Migraine Management. Roger Cady, MD Headache Care Center Springfield, MO

Migraine Management. Roger Cady, MD Headache Care Center Springfield, MO Migraine Management Roger Cady, MD Headache Care Center Springfield, MO Disclosures Objectives The evolution of migraine From benign episodic (benign) headache to potentially a devastating chronic disease

More information

Abortive Agents. Available Strengths. Formulary Limits. Tablet: 5mg, 10mg ODT: 5mg, 10 mg 25mg, 50mg, 100mg. 5mg/act, 20mg/act

Abortive Agents. Available Strengths. Formulary Limits. Tablet: 5mg, 10mg ODT: 5mg, 10 mg 25mg, 50mg, 100mg. 5mg/act, 20mg/act MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Migraine Therapy P&T DATE: 9/12/2017 CLASS: Neurological Disorders REVIEW HISTORY 12/16, 9/15, 2/15, 2/10, 5/07 LOB: MCL

More information

ปวดศ รษะมา 5 ป ก นยาแก ปวดก ย งไม ข น นพ.พาว ฒ เมฆว ช ย โรงพยาบาลนครราชส มา

ปวดศ รษะมา 5 ป ก นยาแก ปวดก ย งไม ข น นพ.พาว ฒ เมฆว ช ย โรงพยาบาลนครราชส มา ปวดศ รษะมา 5 ป ก นยาแก ปวดก ย งไม ข น นพ.พาว ฒ เมฆว ช ย โรงพยาบาลนครราชส มา 1 CONTENT 1 2 3 Chronic Daily Headache Medical Overused Headache Management Headaches are one of the most common symptoms List

More information

ABORTIVE AGENTS. Average cost per 30 days. Form Limits SEROTONIN AGONISTS $ $ Reserved for treatment failure to either Sumatriptan PA; QL

ABORTIVE AGENTS. Average cost per 30 days. Form Limits SEROTONIN AGONISTS $ $ Reserved for treatment failure to either Sumatriptan PA; QL MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Migraine Therapy P&T DATE: 12/11/2018 CLASS: Neurological Disorders REVIEW HISTORY 9/17, 12/16, 9/15, 2/15, 2/10, LOB: MCL

More information

10/31/2017 PRIMARY CARE AND HEADACHE DISCLOSURES WHERE DO THOSE WITH HEADACHE SEEK MEDICAL CARE? Primary Care 67%

10/31/2017 PRIMARY CARE AND HEADACHE DISCLOSURES WHERE DO THOSE WITH HEADACHE SEEK MEDICAL CARE? Primary Care 67% PRIMARY CARE AND HEADACHE Sonja Potrebic MD PhD Regional Headache Specialist Kaiser LAMC 1 WHERE DO THOSE WITH HEADACHE SEEK MEDICAL CARE? Column1 Primary Care 67% Primary Care Headache Specialty Other

More information

Headache. Section 1. Migraine headache. Clinical presentation

Headache. Section 1. Migraine headache. Clinical presentation Section 1 Headache Migraine headache 1 Clinical presentation It is important to recognize just how significant a problem migraine headache is. It has been estimated that migraine affects 11% of the United

More information

Emerging Challenges in Primary Care: Brainstorm: A Symposium on Migraine Treatment and Management

Emerging Challenges in Primary Care: Brainstorm: A Symposium on Migraine Treatment and Management Emerging Challenges in Primary Care: 2017 Brainstorm: A Symposium on Migraine Treatment and Management 1 Faculty Jeff Unger, MD, ABFM, FACE Director, Unger Primary Care Medical Group Rancho Cucamonga,

More information

Management options for Migraine. Prof. Dr. Khwaja Nazimuddin Head Dept. of Internal Medicine BIRDEM

Management options for Migraine. Prof. Dr. Khwaja Nazimuddin Head Dept. of Internal Medicine BIRDEM Management options for Migraine Prof. Dr. Khwaja Nazimuddin Head Dept. of Internal Medicine BIRDEM Assessment The Migraine Disability Assessment Score MIDAS Complete loss of work Partial loss of work Off

More information

TABLE 1. Current Diagnostic Criteria for Migraine Without Aura 2 A. At least 5 attacks fulfilling criteria B-D B. Headache attacks lasting 4-72 hours

TABLE 1. Current Diagnostic Criteria for Migraine Without Aura 2 A. At least 5 attacks fulfilling criteria B-D B. Headache attacks lasting 4-72 hours ANSWERS CONCISE TO FREQUENTLY REVIEW ASKED QUESTIONS FOR CLINICIANS ABOUT MIGRAINE Answers to Frequently Asked Questions About Migraine IVAN GARZA, MD, AND JERRY W. SWANSON, MD Migraine is a common primary

More information

Clinical Learning Days November 10, 2017

Clinical Learning Days November 10, 2017 Migraine Clinical Learning Days November 10, 2017 Alyssa Lettich. MD Neurosciences Institute/Neurosciences Clinical Program Medical Director Headache Disclosures: none Learning Objectives: At the conclusion

More information

Headaches in the Pediatric Emergency Dept

Headaches in the Pediatric Emergency Dept Headaches in Children February 23, 2011 Jinny Tavee, MD Associate Professor Neuromuscular Center Cleveland Clinic Foundation Cleveland, OH 1 Headaches in the Pediatric Emergency Dept Burton Gutierrez Kan

More information

Managing Migraine: Primary Care for Primary Headaches

Managing Migraine: Primary Care for Primary Headaches Managing Migraine: Primary Care for Primary Headaches Faculty Jeffrey Unger, MD, FAAFP, FACE Director, Unger Primary Care Concierge Medical Group, Rancho Cucamonga, California; Director of Metabolic Studies,

More information

Chronic Migraine in Primary Care. December 11 th, 2017 Werner J. Becker University of Calgary

Chronic Migraine in Primary Care. December 11 th, 2017 Werner J. Becker University of Calgary Chronic Migraine in Primary Care December 11 th, 2017 Werner J. Becker University of Calgary Disclosures Faculty: Werner J. Becker Relationships with commercial interests: Grants/Research Support: Clinical

More information

Jessica Ailani MD FAHS Director, Georgetown Headache Center Associate Professor Neurology Medstar Georgetown University Hospital

Jessica Ailani MD FAHS Director, Georgetown Headache Center Associate Professor Neurology Medstar Georgetown University Hospital Jessica Ailani MD FAHS Director, Georgetown Headache Center Associate Professor Neurology Medstar Georgetown University Hospital Honorarium from Current Pain and Headache Reports; Section Editor Unusual

More information

I have no financial relationships to disclose. I will not discuss investigational use of medication in my presentation.

I have no financial relationships to disclose. I will not discuss investigational use of medication in my presentation. I have no financial relationships to disclose. I will not discuss investigational use of medication in my presentation. In 1962, Bille published landmark epidemiologic survey of headache among 9,000 school

More information

Treatment of Primary Headache Syndromes

Treatment of Primary Headache Syndromes Presenter Disclosure Information 2:45 3:45pm Treatment of Primary Headache Syndromes SPEAKER Gerald W. Smetana, MD The following relationships exist related to this presentation: Gerald W.Smetana, MD,

More information

Acute Migraine Treatment: What you and your family should know to help you make the best choices with your doctor

Acute Migraine Treatment: What you and your family should know to help you make the best choices with your doctor Acute Migraine Treatment: What you and your family should know to help you make the best choices with your doctor TAKE CONTROL OF YOUR MIGRAINES! ABOUT THIS PATIENT GUIDE: Migraine attacks are often debilitating

More information

Index. Prim Care Clin Office Pract 31 (2004) Note: Page numbers of article titles are in boldface type.

Index. Prim Care Clin Office Pract 31 (2004) Note: Page numbers of article titles are in boldface type. Prim Care Clin Office Pract 31 (2004) 441 447 Index Note: Page numbers of article titles are in boldface type. A Abscess, brain, headache in, 388 Acetaminophen for migraine, 406 407 headache from, 369

More information

Headache A Practical Approach

Headache A Practical Approach Headache A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD Neurosciences Institute/Neurosciences Clinical Program Medical Director Headache and Pain Development Teams Disclosures:

More information

Preventive treatment of migraine. Rebecca Burch, MD Brigham and Women s Faulkner Hospital Harvard Medical School Boston, MA

Preventive treatment of migraine. Rebecca Burch, MD Brigham and Women s Faulkner Hospital Harvard Medical School Boston, MA Preventive treatment of migraine Rebecca Burch, MD Brigham and Women s Faulkner Hospital Harvard Medical School Boston, MA No disclosures Disclosures Many preventive treatments for migraine are not FDA-approved

More information

Triptans Quantity Limit Program Summary

Triptans Quantity Limit Program Summary Triptans Quantity Limit Program Summary FDA APPROVED INDICATIONS AND DOSAGE 1-13,14,23,24 Agents Amerge (naratriptan) 1, 2.5 tablets Axert (almotriptan) 6.25, 12.5 tablets migraine attacks with/without

More information

Current Migraine Treatment Therapy. Daniel Kassicieh, DO, FAAN

Current Migraine Treatment Therapy. Daniel Kassicieh, DO, FAAN Current Migraine Treatment Therapy Daniel Kassicieh, DO, FAAN Migraine a Disease Process Migraines are a chronic disease process similar to many other chronic medical conditions Migraine has a low mortality

More information

A case of a patient with chronic headache. Focus on Migraine. None related to the presentation Grants to conduct clinical trials from: Speaker bureau:

A case of a patient with chronic headache. Focus on Migraine. None related to the presentation Grants to conduct clinical trials from: Speaker bureau: Chronic Daily Headache Bassel F. Shneker, MD, MBA Associate Professor Vice Chair, OSU Neurology The Ohio State University Wexner Medical Center Financial Disclosures None related to the presentation Grants

More information

Prevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D.

Prevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D. Prevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D. Objectives Present patient case Review epidemiology/pathophysiology

More information

UNDERSTANDING CHRONIC MIGRAINE. Learn about diagnosis, management, and treatment options for this headache condition

UNDERSTANDING CHRONIC MIGRAINE. Learn about diagnosis, management, and treatment options for this headache condition UNDERSTANDING CHRONIC MIGRAINE Learn about diagnosis, management, and treatment options for this headache condition 1 What We re Going to Cover Today The symptoms and phases of migraine Differences between

More information

SIGN on the pharmacological management of migraine

SIGN on the pharmacological management of migraine GUIDELINES SIGN on the pharmacological management of migraine STEVE CHAPLIN In February 2018, the Scottish Intercollegiate Guidelines Network (SIGN) published a new guideline on the pharmacological management

More information

Medication For Migraine Chart: Table 1: Acute Treatment when the attack begins

Medication For Migraine Chart: Table 1: Acute Treatment when the attack begins Medication For Migraine Chart: Table 1: Acute Treatment when the attack begins Page a Analgesics (painkillers) Non-steroidal antiinflammatory drugs (NSAIDs) Prescription required Brand Name Formulation

More information

What is the Effectiveness of OnabotulinumtoxinA (Botox ) in Reducing the Number of Chronic Migraines (CM) in Patients Years Old?

What is the Effectiveness of OnabotulinumtoxinA (Botox ) in Reducing the Number of Chronic Migraines (CM) in Patients Years Old? Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2013 What is the Effectiveness of OnabotulinumtoxinA

More information

Disclosures. Triptans for Kids 5/16/13

Disclosures. Triptans for Kids 5/16/13 5/16/13 Disclosures Triptans for Kids Amy A. Gelfand, MD GelfandA@neuropeds.ucsf.edu Departments of Neurology and Pediatrics UCSF Child Neurology and Headache Center I receive grant funding from: NIH/NINDS

More information

10/13/17. Christy M. Jackson, MD Director, Dalessio Headache Center Scripps Clinic, La Jolla Clinical Professor, Neurosciences UCSD

10/13/17. Christy M. Jackson, MD Director, Dalessio Headache Center Scripps Clinic, La Jolla Clinical Professor, Neurosciences UCSD Christy M. Jackson, MD Director, Dalessio Headache Center Scripps Clinic, La Jolla Clinical Professor, Neurosciences UCSD } Depomed Consultant 2014 to present } Avanir Consultant 2014 to present } Amgen

More information

The best defense is a good offense. Optimizing the Acute Treatment of Migraine. Disclosures 11/10/2017

The best defense is a good offense. Optimizing the Acute Treatment of Migraine. Disclosures 11/10/2017 Optimizing the Acute Treatment of Migraine Brian M. Plato, DO, FAHS Norton Neuroscience Institute Louisville, KY Disclosures Speakers Bureau (personal): Allergan, Depomed, Avanir Research Funding (paid

More information

...SELECTED ABSTRACTS...

...SELECTED ABSTRACTS... The following abstracts, from medical journals containing literature on migraine management, were selected for their relevance to this Special Report supplement. Two Sumatriptan Studies Two double-blind

More information

Headache Master School Japan-Osaka 2016 (HMSJ-Osaka2016) October 23, II. Management of Refractory Headaches

Headache Master School Japan-Osaka 2016 (HMSJ-Osaka2016) October 23, II. Management of Refractory Headaches Headache Master School Japan-Osaka 2016 (HMSJ-Osaka2016) October 23, 2016 II. Management of Refractory Headaches Case presentation 1: A case of intractable daily-persistent headache Keio University School

More information

MEASURE #1: MEDICATION PRESCRIBED FOR ACUTE MIGRAINE ATTACK Headache

MEASURE #1: MEDICATION PRESCRIBED FOR ACUTE MIGRAINE ATTACK Headache MEASURE #1: MEDICATION PRESCRIBED FOR ACUTE MIGRAINE ATTACK Headache Measure Description Percentage of patients age 12 years and older with a diagnosis of migraine who were prescribed a guideline recommended

More information

Understanding. Migraine. Amy, diagnosed in 1989, with her family.

Understanding. Migraine. Amy, diagnosed in 1989, with her family. Understanding Migraine Amy, diagnosed in 1989, with her family. What Is a Migraine? A migraine is a recurring moderate to severe headache. The pain usually occurs on one side of the head. It is typically

More information

Triptan Quantity Limit

Triptan Quantity Limit *- Florida Healthy Kids Triptan Quantity Limit Override(s) Quantity Limit Approval Duration 1 year Oral Tablets Axert (almotriptan) tablets Relpax (eletriptan) tablets 6 tablets (6.25 mg) 12 tablets (12.5

More information

Treatments for migraine

Treatments for migraine Treatments for migraine Information for patients and carers Department of Neurology Aberdeen Royal Infirmary Contents Page About this leaflet Abortive medication for migraine Painkillers Antisickness medication

More information

HEADACHE: Benign or Severe Dr Gobinda Chandra Roy

HEADACHE: Benign or Severe Dr Gobinda Chandra Roy HEADACHE: Benign or Severe Dr Gobinda Chandra Roy Associate Professor, Department of Medicine, Shaheed Suhrawardy Medical College and Hospital Outlines 1. Introduction 2. Classification of headache 3.

More information

COMBINATION THERAPIES PREVENTATIVE THERAPIES BETA BLOCKERS

COMBINATION THERAPIES PREVENTATIVE THERAPIES BETA BLOCKERS ACUTE THEAPIES TIPTANS TICYCLIC ANTIDEPESSANTS When starting acute treatment, healthcare professionals should warn patients about the risk of developing medication-overuse headache. ASPIIN Aspirin (900

More information

Dubai Standards of Care (Migraine)

Dubai Standards of Care (Migraine) Dubai Standards of Care 2018 (Migraine) Preface Migraine is one of the most common problem dealt with in daily practice. In Dubai, the management of migraine is done through various different strategies.

More information

Migraine Migraine Age Specific Prevalence in the United States. Headache International Headache Society Classification

Migraine Migraine Age Specific Prevalence in the United States. Headache International Headache Society Classification 28 Primary Care Medicine Principles and Practice 29 October 28 Professor Peter J. Goadsby Peter.Goadsby@headache.ucsf.edu Department of Neurology Headache International Headache Society Classification

More information

Page: 1 of 6. Aimovig (erenumab-aooe) injection, Ajovy (fremanezumab-vfrm) injection, Emgality (galcanezumab-gnim)

Page: 1 of 6. Aimovig (erenumab-aooe) injection, Ajovy (fremanezumab-vfrm) injection, Emgality (galcanezumab-gnim) Page: 1 of 6 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Last Review Date: November 30, 2018 Description Aimovig (erenumab-aooe) injection, Ajovy (fremanezumab-vfrm)

More information

Headache and Facial Pain. Mohammed ALEssa MBBS, FRCSC Assistant Professor Consultant Otolaryngology,Head & Neck Surgical Oncology

Headache and Facial Pain. Mohammed ALEssa MBBS, FRCSC Assistant Professor Consultant Otolaryngology,Head & Neck Surgical Oncology Headache and Facial Pain Mohammed ALEssa MBBS, FRCSC Assistant Professor Consultant Otolaryngology,Head & Neck Surgical Oncology Introduction It is the most common neurologic complain The diagnosis usually

More information

Chronic Daily Headaches

Chronic Daily Headaches Chronic Daily Headaches ANWARUL HAQ, MD, MRCP(UK), FAHS DIRECTOR BAYLOR HEADACHE CENTER, DALLAS, TEXAS DISCLOSURES: None OBJECTIVES AT THE CONCLUSION OF THIS ACTIVITY, PARTICIPANTS WILL BE ABLE TO: define

More information

Reflections on NICE Headache Guideline. Dr Kay Kennis GPwSI in Headache, Bradford

Reflections on NICE Headache Guideline. Dr Kay Kennis GPwSI in Headache, Bradford Reflections on NICE Headache Guideline Dr Kay Kennis GPwSI in Headache, Bradford Overview The process of guideline development illustrated with the headache guideline Reflections on the process Key recommendations

More information

What You Should Know About Your HEADACHE. Learn more about headache types, triggers, and treatments, when to get help, and how to help yourself

What You Should Know About Your HEADACHE. Learn more about headache types, triggers, and treatments, when to get help, and how to help yourself What You Should Know About Your HEADACHE Learn more about headache types, triggers, and treatments, when to get help, and how to help yourself Introduction The purpose of this brochure is to give you a

More information

Regulatory Status FDA approved indication: Migranal Nasal Spray is indicated for the acute treatment of migraine headaches with or without aura (1).

Regulatory Status FDA approved indication: Migranal Nasal Spray is indicated for the acute treatment of migraine headaches with or without aura (1). Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.60 Subject: Migranal Nasal Spray Page: 1 of 5 Last Review Date: November 30, 2018 Migranal Nasal Spray

More information

Vestibular Migraine. Information for patients and carers. Department of Neurology and Otolaryngology Aberdeen Royal Infirmary

Vestibular Migraine. Information for patients and carers. Department of Neurology and Otolaryngology Aberdeen Royal Infirmary Vestibular Migraine Information for patients and carers Department of Neurology and Otolaryngology Aberdeen Royal Infirmary What is vestibular migraine? Migraine is a disabling headache disorder that affects

More information

Short Clinical Guidelines: Headache, Key Points for Diagnosis and Treatment

Short Clinical Guidelines: Headache, Key Points for Diagnosis and Treatment Clinical Highlights 1. Headache is diagnosed by history and physical examination with limited need for imaging or laboratory tests. 2. Warning signs of possible disorder other than primary headache are:

More information

Migrainous headache, the menstrual cycle and pregnancy. Dr Manuela Fontebasso Headache Specialist, Author and Headache Education Facilitator

Migrainous headache, the menstrual cycle and pregnancy. Dr Manuela Fontebasso Headache Specialist, Author and Headache Education Facilitator Migrainous headache, the menstrual cycle and pregnancy Dr Manuela Fontebasso Headache Specialist, Author and Headache Education Facilitator What sort of headaches? Migraine with and without aura Tension

More information

Drug List. Improving Outcomes in Episodic Migraine. Presenter Disclosure Information. Learning Objectives. Improving Outcomes in Episodic Migraine

Drug List. Improving Outcomes in Episodic Migraine. Presenter Disclosure Information. Learning Objectives. Improving Outcomes in Episodic Migraine 2:15 3:30 pm Improving Outcomes in Episodic Migraine SPEAKERS Brian E. McGeeney, M.D., M.P.H. D. Michael Ready, MD, FAHS Presenter Disclosure Information The following relationships exist related to this

More information

ARxCH. Annual Review of Changes in Healthcare. Calcitonin Gene-Related Peptide Receptors and the Prevention of Migraines. Abstract

ARxCH. Annual Review of Changes in Healthcare. Calcitonin Gene-Related Peptide Receptors and the Prevention of Migraines. Abstract Calcitonin Gene-Related Peptide Receptors and the Prevention of Migraines Brian Schuler, PharmD Candidate 2018 1 1 University of Findlay College of Pharmacy Abstract Migraines are the third most prevalent

More information

Manging Migraine in Children & Adults

Manging Migraine in Children & Adults Manging Migraine in Children & Adults Heather Sim, Chief Executive heather.sim85@gmail.com RCN School Nurses Conference August 2017 1 What are migraines and what triggers them? How do migraines affect

More information

Anti-Migraine Agents

Anti-Migraine Agents DRUG POLICY BENEFIT APPLICATION Anti-Migraine Agents Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association CGRP Page 1 of 8 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: CGRP (calcitonin gene-related peptide) Prime Therapeutics will review Prior Authorization requests

More information

Migraine Acute treatment

Migraine Acute treatment Migraine Acute treatment Elizabeth Loder, MD, MPH Professor of Neurology, Harvard Medical School Chief, Division of Headache, Department of Neurology, Brigham and Women s Hospital, Boston, MA Disclosures

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association CGRP Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: CGRP (calcitonin gene-related peptide) Prime Therapeutics will review Prior Authorization requests

More information

Migraine is a primary headache disorder ... REPORTS... Migraine: Diagnosis, Management, and New Treatment Options

Migraine is a primary headache disorder ... REPORTS... Migraine: Diagnosis, Management, and New Treatment Options ... REPORTS... Migraine: Diagnosis, Management, and New Treatment Options R. Michael Gallagher, DO; and F. Michael Cutrer, MD Abstract Objective: The safety and tolerability of medications used to treat

More information

WHY IS MIGRAINE IMPORTANT

WHY IS MIGRAINE IMPORTANT WHY IS MIGRAINE IMPORTANT Migraine is a complex disorder characterized by recurrent episodes of headache, most often unilateral and in some cases associated with visual or sensory symptoms collectively

More information

Migraine Controversies in Women s Health. Professor Peter J. Goadsby 5 December Department of Neurology

Migraine Controversies in Women s Health. Professor Peter J. Goadsby 5 December Department of Neurology Migraine 2008 Controversies in Women s Health 5 December 2008 Professor Peter J. Goadsby Peter.Goadsby@headache.ucsf.edu Department of Neurology Headache International Headache Society Classification Primary

More information

Zolmitriptan nasal spray provides fast relief of migraine symptoms and is preferred by patients: a Swedish study of preference in clinical practice

Zolmitriptan nasal spray provides fast relief of migraine symptoms and is preferred by patients: a Swedish study of preference in clinical practice J Headache Pain (2004) 5:237 242 DOI 10.1007/s10194-004-0132-3 ORIGINAL Carl G.H. Dahlöf Mattias Linde Erika Kerekes Zolmitriptan nasal spray provides fast relief of migraine symptoms and is preferred

More information

Paediatric headaches. Dr Jaycen Cruickshank Director of Clinical Training Ballarat Health Services. Brevity, levity, repetition

Paediatric headaches. Dr Jaycen Cruickshank Director of Clinical Training Ballarat Health Services. Brevity, levity, repetition Paediatric headaches Dr Jaycen Cruickshank Director of Clinical Training Ballarat Health Services Brevity, levity, repetition Paediatric)headache?)! Headache!in!children!is!not!that!common.!The!question!is!which!headaches!do!I!

More information

Optimizing triptan therapy in clinical practice

Optimizing triptan therapy in clinical practice Review Optimizing triptan therapy in clinical practice Carlo Lisotto* & Giorgio Zanchin Practice Points The prevalence of migraine is 12 16% of the general population and is two- to threetimes higher in

More information

Headache Mary D. Hughes, MD Neuroscience Associates

Headache Mary D. Hughes, MD Neuroscience Associates Headache Mary D. Hughes, MD Neuroscience Associates Case 1 22 year old female presents with recurrent headaches. She has had headaches for the past 3 years. They start on the right side of her head and

More information

Clinical Policy: Triptans Reference Number: CP.CPA.217 Effective Date: Last Review Date: Line of Business: Commercial

Clinical Policy: Triptans Reference Number: CP.CPA.217 Effective Date: Last Review Date: Line of Business: Commercial Clinical Policy: Reference Number: CP.CPA.217 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory

More information

UTILIZATION MANAGEMENT CRITERIA

UTILIZATION MANAGEMENT CRITERIA SUMATRIPTAN (ALSUMA, IMITREX, SUMAVEL DOSEPRO, ZECUITY ) UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: BRAND (generic) NAME: Serotonin 5-HT1 receptor agonists Imitrex (sumatriptan), Alsuma (sumatriptan),

More information

Migranal Nasal Spray. Migranal Nasal Spray (dihydroergotamine) Description

Migranal Nasal Spray. Migranal Nasal Spray (dihydroergotamine) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.60 Subject: Migranal Nasal Spray Page: 1 of 5 Last Review Date: June 22, 2017 Migranal Nasal Spray

More information

Get ahead of the ACHE: Monoclonal Antibodies in Migraine Prevention

Get ahead of the ACHE: Monoclonal Antibodies in Migraine Prevention Get ahead of the ACHE: Monoclonal Antibodies in Migraine Prevention Amanda Janisch, PharmD PGY2 Ambulatory Care Pharmacy Resident MCHS SWMN, Mankato, MN 2018 MFMER slide-1 Disclosures No financial interest

More information

ONZETRA XSAIL (sumatriptan) nasal powder

ONZETRA XSAIL (sumatriptan) nasal powder ONZETRA XSAIL (sumatriptan) nasal powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy

More information

HEADACHE. Dr Nick Pendleton. September Headache

HEADACHE. Dr Nick Pendleton. September Headache HEADACHE Dr Nick Pendleton September 2017 Headache Tension Type Headache Cranial Nerve Examination Migraine Migraine Treatment Medication Overuse Headache Headache Red Flags Sinusitis Headache Raised ICP

More information

25/09/2018 HEADACHE. Dr Nick Pendleton

25/09/2018 HEADACHE. Dr Nick Pendleton HEADACHE Dr Nick Pendleton September 2018 1 Small Group Work Tension Type Headache Cranial Nerve Examination Migraine Migraine Treatment Medication Overuse Headache Headache Red Flags Sinusitis Headache

More information

Subject: CGRP Inhibitors

Subject: CGRP Inhibitors ARCHIVED (NOT ACTIVE RETIRED) Archived: 08/01/18 09-J2000-98 Original Effective Date: 06/15/18 Reviewed: 05/09/18 Revised: 08/01/18 Next Review: ARCHIVED (NOT ACTIVE RETIRED) Subject: CGRP Inhibitors THIS

More information

MEASURE #4: Overuse of Barbiturate Containing Medications for Primary Headache Disorders Headache

MEASURE #4: Overuse of Barbiturate Containing Medications for Primary Headache Disorders Headache MEASURE #4: Overuse of Barbiturate Containing Medications for Primary Headache Disorders Headache Measure Description Percentage of patients age 18 years old and older with a diagnosis of primary headache

More information

Headache: A case-based approach

Headache: A case-based approach Headache: A case-based approach Rebecca Burch, MD John R. Graham Headache Center Department of Neurology Brigham and Women s Faulkner Hospital Harvard Medical School Boston, MA Disclosure of Financial

More information

Disclosures. Learning Objectives. Treatment Of Menstrual Migraine 11/10/2017. Research grants Aralez, Allergan

Disclosures. Learning Objectives. Treatment Of Menstrual Migraine 11/10/2017. Research grants Aralez, Allergan Treatment Of Menstrual Migraine Christine Lay, MD Director, Centre for Headache Associate Professor University of Toronto Disclosures Research grants Aralez, Allergan Unrestricted educational grants Aralez,

More information

Ishaq Abu Arafeh Consultant Paediatrician Royal Hospital for Children, Glasgow Forth Valley Royal Hospital, Larbert

Ishaq Abu Arafeh Consultant Paediatrician Royal Hospital for Children, Glasgow Forth Valley Royal Hospital, Larbert Ishaq Abu Arafeh Consultant Paediatrician Royal Hospital for Children, Glasgow Forth Valley Royal Hospital, Larbert Childhood headache: Is it really difficult to manage? It shouldn t be... But it can be...

More information

THE WOMAN WHO COULD NOT DECIDE WHICH MEDICATION TO TAKE

THE WOMAN WHO COULD NOT DECIDE WHICH MEDICATION TO TAKE Rapoport Ch 05.qxd 10/15/08 1:06 PM Page 25 CHAPTER 5 THE WOMAN WHO COULD NOT DECIDE WHICH MEDICATION TO TAKE ALLAN PURDY, MD, FRCPC FRED SHEFTELL, MD ALAN RAPOPORT, MD STEWART J. TEPPER, MD Case History

More information

Migraine: Past, Present and Future Edward O Sullivan September 12 th 2015 Dublin 12/09/2015

Migraine: Past, Present and Future Edward O Sullivan September 12 th 2015 Dublin 12/09/2015 1 Migraine: Past, Present and Future Edward O Sullivan September 12 th 2015 Dublin Tour de France 2015: Mark Renshaw Yesterday at the end of the stage 17 I came down with a migraine before the final climb

More information

What else do you need to know? Presenter Disclosure Information. Learning Objectives. Rita, a 31-year-old mother

What else do you need to know? Presenter Disclosure Information. Learning Objectives. Rita, a 31-year-old mother 10:45 11:45 am Migraine Headaches: Tools for Successful Management Presenter Disclosure Information The following relationships exist related to this presentation: M. Susan Burke, MD, FACP: Speakers Bureau

More information

Maximizing Relief: A Personalized Approach to the Acute Treatment of Migraine in an Era of New Therapeutic Delivery Mechanisms

Maximizing Relief: A Personalized Approach to the Acute Treatment of Migraine in an Era of New Therapeutic Delivery Mechanisms CME Maximizing Relief: A Personalized Approach to the Acute Treatment of Migraine in an Era of New Therapeutic Delivery Mechanisms Course Director Stewart J. Tepper, MD Geisel School of Medicine at Dartmouth

More information

What is new in the migraine world! Modar Khalil Consultant neurologist Hull Royal Infirmary

What is new in the migraine world! Modar Khalil Consultant neurologist Hull Royal Infirmary What is new in the migraine world! Modar Khalil Consultant neurologist Hull Royal Infirmary Overview Understanding the burden Commonly used terms Acute therapy What we currently have What we are going

More information

HEADACHE: Types, Tips & Treatment Suggestions

HEADACHE: Types, Tips & Treatment Suggestions Headaches are one of the most common complaints patients present with in primary care settings. They are often correlated with stress, tension and a litany of existing medical conditions. Often, patients

More information